Technology
Health
Pharmaceutical

Nightstar Therapeutics

$25.45
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.03 (-0.12%) Today
-$0.03 (-0.12%) Today

Why Robinhood?

You can buy or sell NITE and other stocks, options, ETFs, and crypto commission-free!

About

Nightstar Therapeutics plc American Depositary Shares, also called Nightstar Therapeutics, is a clinical-stage gene therapy holding company, which engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. Its pipeline includes NSR-REP1, for the treatment of choroideremia; NSR-RPGR, for the treatment of X-linked retinitis pigmentosa; and NSR-BEST1, for the treatment of vitelliform macular dystrophy. Read More The company was founded by Robert MacLaren on July 6, 2017 and is headquartered in London, the United Kingdom.

Employees
47
Headquarters
London, Greater London
Founded
2017
Market Cap
853.22M
Price-Earnings Ratio
β€”
Dividend Yield
β€”
Average Volume
196.33K
High Today
$25.49
Low Today
$25.43
Open Price
$25.45
Volume
968.00
52 Week High
$29.55
52 Week Low
$9.59

Collections

Technology
Health
Pharmaceutical
Therapy
Medical
2017 IPO
UK
Europe

News

NasdaqMay 8

Nightstar Therapeutics PLC Shareholders Approve Scheme of Arrangement for Acquisition By Biogen at General Meeting and Court Meeting Held on 8 May 2019

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION WALTHAM, Mass. and LONDON, May 08, 2019 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc ("Nightstar") is pleased to announce that, at the General Meeting and the Court Meeting held earlier today in connection with the recommended acquisition of the entire issued and to be issu...

33
NasdaqApr 26

Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Nightstar Shareholders Vote β€œFOR” Proposed Acquisition by Biogen

Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Nightstar Shareholders Vote "FOR" Proposed Acquisition by Biogen WALTHAM, Mass. and LONDON, April 26, 2019 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc ("Nightstar") (NASDAQ:NITE) today announced that both leading independent proxy advisory firms, Institutional Shareholder Services Inc. ("ISS") and Glass Lewis & Co. ("Glass Lewis"), have recommended that Nightstar shareholders vote "FOR" the proposals relating to the proposed acquisition of Nig...

17

Earnings

-$0.52
-$0.40
-$0.27
-$0.15
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.38 per share
Actual
Expected Jun 5, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.